ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2022
Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07271771 (The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Beyond bone effects: the role of denosumab in muscle Health - A systematic review.Aging clinical and experimental research · 2026Pooled it
- Anti-resorptive and anabolic therapies improve Falls Risk Assessment Score (FRAS) in postmenopausal women with type 2 diabetes mellitus.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Trial
- Trial
- Trial
- Anti-osteoporotic Pharmacotherapy and Muscle Outcomes in Osteosarcopenia: a Source-Verified Translational Evidence Map.Calcified tissue international · 2026Review
- Denosumab therapy is associated with a reduced risk of clinically diagnosed rotator cuff tears: a multi-institutional real-world cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Comparison of Denosumab and Bisphosphonates for Sarcopenia in Postmenopausal Osteoporosis.Journal of clinical medicine · 2026Article
- Impact of Denosumab Adherence on Renal Function and Mortality Rates in Type 2 Diabetes Patients With Osteoporosis.The Kaohsiung journal of medical sciences · 2026Article
- The effect of osteoporosis medication on bite force in older adults: a prospective clinical study.Clinical oral investigations · 2026Article
- Development of Functional Performance, Bone Mineral Density, and Back Pain Under Specific Pharmacological Osteoporosis Therapy in an Elderly, Multimorbid Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Bridging bone and muscle: ontology-driven prioritization of candidate genes at the osteoporosis-sarcopenia interface by gene ontology reverse lookup.Frontiers in genetics · 2026Article
- Pain in Osteoporosis: Current and Future Strategies.Drugs & aging · 2025Review
- Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?International journal of molecular sciences · 2025Review
- Calf circumference predicts changes of bone mineral density in postmenopausal osteoporotic women receiving denosumab.Aging clinical and experimental research · 2025Article
- Beyond Bone Remodeling: Denosumab's Multisystemic Benefits in Musculoskeletal Health, Metabolism, and Age-Related Diseases-A Narrative Review.Biomedicines · 2025Review
- Effects of denosumab and zoledronic acid on postmenopausal osteoporosis, bone density, and fat-free mass.Archives of osteoporosis · 2025Article
- Extra-osseous Roles of the RANK-RANKL-OPG Axis with a Focus on Skeletal Muscle.Current osteoporosis reports · 2024Review
- Potential application of anti-osteoporotic therapy to relieve sarcopenia in the elderly.Annals of medicine and surgery (2012) · 2023Review
- Does Denosumab Really Improve Muscle Strength? Current Evidence Is Weak.Annals of geriatric medicine and research · 2023Article
- Denosumab's Therapeutic Effect for Future Osteosarcopenia Therapy : A Systematic Review and Meta-Analysis.Annals of geriatric medicine and research · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examined the effects of denosumab compared to bisphosphonates and vitamin D alone on muscle performance in patients with low BMD. While grip force improved in both the denosumab and bisphosphonate group, a superior increase in chair rising test force was observed in the denosumab group.
introductionThe aim of this study was to investigate the effect of the anti-resorptive agent denosumab (Dmab) on upper and lower limb muscle performance compared to bisphosphonate (BP) treatment and vitamin D supplementation alone (i.e., basic therapy) in patients with low BMD.
methodsThis retrospective, propensity score-matched (sex, age, BMI, follow-up time) cohort study included 150 osteopenic or osteoporotic patients receiving basic (n = 60), BP (n = 30) or Dmab (n = 60) therapy. All patients underwent a musculoskeletal assessment at baseline and follow-up, including DXA, laboratory bone metabolism parameters, grip force, and chair rising test mechanography. Mean annual percentage changes were calculated and compared between study groups.
resultsAfter a mean follow-up period of 17.6 ± 9.0 months, a significantly higher increase in grip force in both the Dmab (p < 0.001) and BP group (p = 0.001) compared to the vitamin D group was observed (vitamin D = - 6.1 ± 10.2%; BP = + 0.8 ± 8.2%; Dmab = + 5.1 ± 25.5%). The Dmab group showed a significantly higher increase in chair rising test force compared to the BP group (vitamin D = + 5.8 ± 12.7%; BP = + 0.9 ± 8.6%; Dmab = + 8.2 ± 14.4%; Dmab vs. BP p = 0.03). Neither the changes in BMD nor in bone metabolic parameters were associated with changes in muscle performance.
conclusionDmab resulted in increased muscle strength in the upper and lower limbs, indicating systemic rather than site-specific effects as compared to BP. Based on these findings, Dmab might be favored over other osteoporosis treatments in patients with low BMD and poor muscle strength.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.